KRS Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

KRS Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-260	Closed	-$201K	–	128
2026 Q1	$201K	Hold	260	–	–	0.12%	115
2025 Q4	$201K	Buy	+260	New	+$177K	0.12%	115
2025 Q2	–	Sell	-330	Closed	-$209K	–	110
2025 Q1	$209K	Hold	330	–	–	0.17%	100
2024 Q4	$235K	Hold	330	–	–	0.17%	103
2024 Q3	$347K	Hold	330	–	–	0.25%	75
2024 Q2	$347K	Hold	330	–	–	0.26%	81
2024 Q1	$318K	Hold	330	–	–	0.26%	88
2023 Q4	$290K	Hold	330	–	–	0.27%	88
2023 Q3	$272K	Sell	330 -15	-4%	-$11.8K	0.29%	86
2023 Q2	$248K	Hold	345	–	–	0.25%	95
2023 Q1	$283K	Sell	345 -10	-3%	-$7.54K	0.32%	87
2022 Q4	$256K	Buy	355 +40	+13%	+$29.5K	0.35%	89
2022 Q3	$216K	Buy	+315	New	+$198K	0.3%	91
2022 Q2	–	Sell	-315	Closed	-$220K	–	108
2022 Q1	$220K	Hold	315	–	–	0.24%	108
2021 Q4	$198K	Buy	+315	New	+$194K	0.17%	118

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

KRS Capital Management's REGN Position: Q2 2026 in Review

KRS Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 260 shares — an estimated $201K sold.

KRS Capital Management first reported a position in REGN in Q4 2021 and held it in 15 quarters. The position peaked at $347K in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

KRS Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
KRS Capital Management sold 260 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $201K.
KRS Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 15 quarters.
KRS Capital Management's Regeneron Pharmaceuticals position peaked at $347K in Q3 2024.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on KRS Capital Management's 13F filing for Q2 2026, filed 20 Jul 2026.